Orforglipron Proved Safe for Diabetes Heart Health
The oral medication demonstrated cardiovascular safety and better weight control than insulin glargine in a trial.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Would you prefer using new oral medications over traditional insulin for managing your diabetes treatment?
The phase 3 ACHIEVE-4 trial has demonstrated that the oral drug orforglipron is cardiovascularly safe for adults living with type 2 diabetes. The study found the treatment effectively managed blood sugar and body weight compared to insulin glargine.
Why it matters
This development offers an alternative treatment pathway for adults with type 2 diabetes by providing a non-insulin option that may reduce the risk of hypoglycemia. It shifts the focus toward oral therapies that prioritize both metabolic control and cardiovascular safety.
In the phase 3 ACHIEVE-4 trial involving 2,749 adults, orforglipron achieved noninferiority to insulin glargine regarding major adverse cardiovascular events. The findings were measured over a median follow-up of 104 weeks.
The players
ACHIEVE-4 Trial
A clinical study investigating the cardiovascular safety and efficacy of orforglipron in adults with type 2 diabetes.
The Lancet
A leading medical journal that published the results of the phase 3 ACHIEVE-4 study.
The details
Participants in the trial received either a daily oral dose of orforglipron, escalated up to 36 mg, or titrated insulin glargine. The study found that orforglipron resulted in an 8.9% greater reduction in body weight and a 0.50 percentage point lower HbA1C level at week 52 compared to insulin. While orforglipron showed a significantly lower rate of hypoglycemia, it was associated with a higher incidence of gastrointestinal side effects and a higher study discontinuation rate than insulin.
Timeline
Week 52 marked the primary measurement of HbA1C and weight reduction outcomes.
Week 104 was the point at which the median follow-up period for the study concluded.
September 30, 2026, saw the official publication of the ACHIEVE-4 results in The Lancet.
Health Landscape
This research follows the recent trend of evaluating newer, oral therapies against established insulin protocols for long-term diabetes management. These findings build on the safety foundation required before the ongoing ATTAIN-Outcomes study can determine if the drug reduces cardiovascular events.
Adults managing type 2 diabetes may want to discuss the potential benefits and side-effect profiles of oral medications like orforglipron with their physician. It is essential to monitor for gastrointestinal symptoms and compare them against the risks associated with existing insulin-based therapies.
The takeaway
The ACHIEVE-4 trial highlights that non-insulin, oral treatments can maintain cardiovascular safety while offering distinct advantages in weight management for diabetes patients. Always consult your endocrinologist to determine if your current management plan aligns with the latest clinical evidence.
Further reading
For more information on current treatment options, visit our Diabetes section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Would you prefer using new oral medications over traditional insulin for managing your diabetes treatment?
